MAP3K19 and idiopathic pulmonary fibrosis: Thus, the therapeutic targeting of human MAP3K19 via a siRNA approach significantly reduced pulmonary fibrosis as assessed both using biochemical and transcript analysis approaches in a humanized C.B-17SCID/bg model of IPF.